Articles related to DEPRESSION

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

In the phase III trial for zuranolone, 67.4% of patients who received an initial 2-week course at the 30-mg dose level initially achieved a 50% or greater reduction from baseline on the HAMD-17. Over the following year, half of those patients required additional 2-week courses of therapy. Of the group who received the 50-mg dose, only 25% needed subsequent courses.

In this interview with Dr. Wendy Marsh, director of the Bipolar Disorders and Depression Specialty Clinics at the University of Massachusetts Chan Medical School, she discusses how treatment can better address quality-of-life issues for individuals with bipolar depression.

This report on learnings shows that it is crucial to educate primary healthcare professionals on how to spot people who may commit suicide in their later years (eg, using “The 5 Ds” — Deadly methods, Depression, Disease & Disability, Disconnectness, and Development) and how to adopt prevention measures.

SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.

This cohort study discovered that depression, anxiety, perceived stress, loneliness, and worry about COVID-19 were prospectively associated with a 1.3- to 1.5-fold increased risk of self-reported post-COVID-19 conditions, as well as an increased risk of daily life impairment related to post-COVID-19 conditions.